Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Need For Focused Pharmacovigilance in the Face of Rapid COVID-19 Vaccine Development

Author(s): Upinder Kaur and Sankha Shubhra Chakrabarti*

Volume 18, Issue 3, 2023

Published on: 12 October, 2022

Page: [273 - 275] Pages: 3

DOI: 10.2174/1574886317666220928151519

Next »
[1]
Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med 2021; 385(7): 585-94.
[http://dx.doi.org/10.1056/NEJMoa2108891] [PMID: 34289274]
[2]
Andrews N, Stowe J, Kirsebom F, et al. COVID-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N Engl J Med 2022; 386(16): 1532-46.
[http://dx.doi.org/10.1056/NEJMoa2119451] [PMID: 35249272]
[3]
Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: Test negative case-control study. BMJ 2021; 373(1088): n1088.
[http://dx.doi.org/10.1136/bmj.n1088] [PMID: 33985964]
[4]
Desai D, Khan AR, Soneja M, et al. Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: A test-negative, case-control study. Lancet Infect Dis 2022; 22(3): 349-56.
[http://dx.doi.org/10.1016/S1473-3099(21)00674-5] [PMID: 34826383]
[5]
Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19. N Engl J Med 2021; 384(23): 2187-201.
[http://dx.doi.org/10.1056/NEJMoa2101544] [PMID: 33882225]
[6]
Kim AY, Woo W, Yon DK, et al. Thrombosis patterns and clinical outcome of COVID-19 vaccine-induced immune thrombotic thrombo-cytopenia: A systematic review and meta-analysis. Int J Infect Dis 2022; 119: 130-9.
[http://dx.doi.org/10.1016/j.ijid.2022.03.034] [PMID: 35339716]
[7]
Oster ME, Shay DK, Su JR, et al. Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021. JAMA 2022; 327(4): 331-40.
[http://dx.doi.org/10.1001/jama.2021.24110] [PMID: 35076665]
[8]
Liu J, Wang J, Xu J, et al. Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines. Cell Discov 2021; 7(1): 99.
[http://dx.doi.org/10.1038/s41421-021-00329-3] [PMID: 34697287]
[9]
Kaur U, Ojha B, Pathak BK, et al. A prospective observational safety study on ChAdOx1 nCoV-19 corona virus vaccine (recombinant) use in healthcare workers- first results from India. EClinicalMedicine 2021; 38: 101038.
[http://dx.doi.org/10.1016/j.eclinm.2021.101038] [PMID: 34505032]
[10]
Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 2020; 383(27): 2603-15.
[http://dx.doi.org/10.1056/NEJMoa2034577] [PMID: 33301246]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy